Addressing the Critical Gap in Biological Therapies for Inflammatory Bowel Disease in Syria.
作者信息
Alhalabi Marouf Mouhammad
机构信息
Department of Gastroenterology / Internal Medicine, Damascus Hospital, Damascus, Syria.
出版信息
Avicenna J Med. 2025 May 21;15(2):92-93. doi: 10.1055/s-0045-1809039. eCollection 2025 Apr.
Abstract
摘要
相似文献
1
Addressing the Critical Gap in Biological Therapies for Inflammatory Bowel Disease in Syria.解决叙利亚炎症性肠病生物疗法的关键差距。
Avicenna J Med. 2025 May 21;15(2):92-93. doi: 10.1055/s-0045-1809039. eCollection 2025 Apr.
2
Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: A systematic review.在欧洲就诊的叙利亚和厄立特里亚移民的传染病特征：系统评价。
Travel Med Infect Dis. 2018 Sep-Oct;25:65-76. doi: 10.1016/j.tmaid.2018.04.014. Epub 2018 Apr 24.
3
Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.心理疗法对炎症性肠病的疾病活动、心理共病和生活质量的影响：系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):189-199. doi: 10.1016/S2468-1253(16)30206-0. Epub 2017 Jan 18.
4
Challenges in IBD Research 2024: Novel Technologies.2024 年炎症性肠病研究面临的挑战：新技术。
Inflamm Bowel Dis. 2024 May 23;30(Suppl 2):S30-S38. doi: 10.1093/ibd/izae082.
5
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.21 世纪全球炎症性肠病的发病率和流行率：基于人群的系统综述研究。
Lancet. 2017 Dec 23;390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0. Epub 2017 Oct 16.
6
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning.炎症性肠病的现代先进疗法：实际考量与定位
Clin Gastroenterol Hepatol. 2025 Feb;23(3):454-468. doi: 10.1016/j.cgh.2024.06.050. Epub 2024 Aug 13.
7
Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.炎症性肠病中艰难梭菌感染的管理：AGA 研究所临床实践更新委员会的专家评论。
Clin Gastroenterol Hepatol. 2017 Feb;15(2):166-174. doi: 10.1016/j.cgh.2016.10.024.
8
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation.肠道生物标志物、微生物群组成以及炎症性肠病的遗传易感性作为帕金森病表现的预测指标。
J Parkinsons Dis. 2025 May 7:1877718X251328567. doi: 10.1177/1877718X251328567.
9
Older people and inflammatory bowel disease: a systematic review.老年人与炎症性肠病：一项系统综述
J Clin Nurs. 2008 Nov;17(11c):400-6. doi: 10.1111/j.1365-2702.2008.02577.x.
10
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial.炎症性肠病患者在接受先进疗法后症状缓解情况下的内镜缓解达标治疗（QUOTIENT）：一项开放标签、多中心、实用性随机对照试验的原理、设计与方案
BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615.
本文引用的文献
1
Syria's Bashar al-Assad: the crimes of a physician.叙利亚的巴沙尔·阿萨德：一位医生的罪行。
Lancet. 2025 Jan 11;405(10473):119. doi: 10.1016/S0140-6736(24)02791-0. Epub 2024 Dec 20.
2
The landscape of new therapeutic opportunities for IBD.炎症性肠病治疗新机遇的前景。
Adv Pharmacol. 2024;101:1-83. doi: 10.1016/bs.apha.2024.10.011. Epub 2024 Oct 30.
3
Biosimilarity. Do not confuse biosimilar and biocopy. Example of tenecteplase.生物相似性。不要将生物相似药与生物仿制药混淆。以替奈普酶为例。
Ann Pharm Fr. 2023 Nov;81(6):942-949. doi: 10.1016/j.pharma.2023.07.001. Epub 2023 Jul 6.
4
Positioning biologics in the treatment of IBD: A practical guide生物制剂在炎症性肠病治疗中的定位：实用指南
Curr Res Pharmacol Drug Discov. 2022 Apr 28;3:100104. doi: 10.1016/j.crphar.2022.100104. eCollection 2022.
5
Unmet needs in inflammatory bowel disease.炎症性肠病中未满足的需求。
Curr Res Pharmacol Drug Discov. 2021 Nov 30;2:100070. doi: 10.1016/j.crphar.2021.100070. eCollection 2021.
6
Substandard and falsified medical products: bibliometric analysis and mapping of scientific research.不合格和伪造的医疗产品：科学研究的文献计量分析和绘制图谱。
Global Health. 2021 Sep 23;17(1):114. doi: 10.1186/s12992-021-00766-5.
7
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.生物制剂和小分子抑制剂治疗炎症性肠病在美国医保政策中的市场准入分析。
Dig Dis Sci. 2019 Sep;64(9):2478-2488. doi: 10.1007/s10620-019-05594-7. Epub 2019 Mar 28.
8
Biosimilars: Implications for Clinical Practice.生物类似药：对临床实践的影响。
J Oncol Pract. 2017 Sep;13(9_suppl):24s-31s. doi: 10.1200/JOP.2017.025734.
9
Health care in Syria before and during the crisis.叙利亚危机之前及危机期间的医疗保健情况。
Avicenna J Med. 2012 Jul;2(3):51-53. doi: 10.4103/2231-0770.102275.
Zotero 插件